Literature DB >> 7752021

Cost of ribavirin therapy for respiratory syncytial virus infection.

E D Marquardt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7752021     DOI： 10.1016/s0022-3476(95)70434-5

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  4 in total

1.  Use of cotton rats to evaluate the efficacy of antivirals in treatment of measles virus infections.

Authors:  P R Wyde; D K Moore-Poveda; E De Clercq; J Neyts; A Matsuda; N Minakawa; E Guzman; B E Gilbert
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

2.  Inhibition of respiratory syncytial virus infections with morpholino oligomers in cell cultures and in mice.

Authors:  Shen-Hao Lai; David A Stein; Antonieta Guerrero-Plata; Sui-Ling Liao; Teodora Ivanciuc; Chao Hong; Patrick L Iversen; Antonella Casola; Roberto P Garofalo
Journal:  Mol Ther       Date:  2008-04-29       Impact factor: 11.454

Review 3.  Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.

Authors:  Tony Velkov; Nusaibah Abdul Rahim; Qi Tony Zhou; Hak-Kim Chan; Jian Li
Journal:  Adv Drug Deliv Rev       Date:  2014-11-12       Impact factor: 15.470

Review 4.  Emerging drugs for respiratory syncytial virus infection.

Authors:  Wieslawa Olszewska; Peter Openshaw
Journal:  Expert Opin Emerg Drugs       Date:  2009-06       Impact factor: 4.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.